<DOC>
	<DOCNO>NCT02597829</DOCNO>
	<brief_summary>A prospective open label trial adult patient active Crohn 's disease determine plasma concentration certolizumab pegol correlate mucosal healing .</brief_summary>
	<brief_title>Does Clinical Response Correlate With Serum Certolizumab Levels ?</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subject Inclusion Criteria 1 . Males females ≥ 18 ≤ 70 year age . 2 . Diagnosis colonic , ileocolonic , ileal Crohn 's disease ≥ 3 month confirm radiography , histology , and/or endoscopy time past . 3 . Moderately severely active Crohn 's disease define Harvey Bradshaw Index ( HBI ) ≥ 8 baseline AND least one following : Abnormal CRP screening ( &gt; Upper Limit Normal [ ULN ] accept lab assay ) Elevated fecal calprotectin screening ( &gt; ULN accept lab assay ) Endoscopic evidence ( colonoscopy small bowel video capsule endoscopy ) active Crohn 's ulceration within 3 month baseline screen 4 . Taking stable dose corticosteroid ( oral anorectal ) ≤ 40 mg/day , equivalent , least 2 week prior baseline . 5 . Taking stable dose 5ASA , antibiotic , antidiarrheal , analgesic , and/or probiotic least 4 week prior baseline . 6 . Taking stable dose immunosuppressant least 8 week prior baseline . 7 . Have screen laboratory test result within follow parameter : Hemoglobin ≥ 8.5 g/dL WBC count ≥ 3.5 x 103 µL Neutrophils ≥ 1.5 x 103 µL Platelets ≥ 100 x 103 µL Serum creatinine &lt; 1.7 mg/dL AST ALT concentration must within 2 time ULN range laboratory conduct test 8 . Subject negative TB Screening Assessment ( include PPD test ) negative chest xray ( posterioranterior PA lateral view ) within 2 month prior screen . 9 . If female , subject either childbearing potential , define postmenopausal ( &gt; 45 year age amenorrhea least 18 month ) surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy otherwise incapable pregnancy ) childbearing potential practicing follow method birth control : Implants , injectables , intrauterine device ( IUDs ) , intrauterine hormone release system ( IUS ) , hormonal prescription oral contraceptive , contraceptive patch , double barrier method Male partner sterilization Not heterosexually active 10 . Negative serum pregnancy test screen negative urine pregnancy test baseline . 11 . If male , surgically sterile , heterosexually active woman child bear potential , subject must agree use double barrier method birth control donate sperm study 12 week receive study agent . 12 . Subject must able willing give write informed consent comply requirement study protocol . Subject Exclusion Criteria 1 . Any contraindication use certolizumab pegol include : active latent TB , active viral infection chronic recurrent infection , evidence dysplasia history malignancy , congestive heart failure ( CHF ) , demyelinate disease cytopenia . 2 . Subject previously receive treatment certolizumab pegol previously participate certolizumab pegol study . 3 . Has complication Crohn 's disease symptomatic stricture stenosis , short bowel syndrome , manifestation might anticipate require surgery , could preclude use HBI ass response therapy , would possibly confound ability assess effect treatment certolizumab pegol . 4 . Subject surgical bowel resection ( ) within 6 month intra abdominal surgery within 3 month prior baseline . 5 . Subject ostomy ileoanal pouch . 6 . Subject receive antiTNF agent &lt; 8 week prior baseline . 7 . Subject receive immunomodulatory biologic agent , &lt; 8 week within 5 halflives agent prior baseline , whichever longer 8 . Subject know infected HIV , Hepatitis B Hepatitis C 9 . Subject positive Clostridium difficile ( C. difficile ) toxin stool assay Screening period . 10 . Subject severe , progressive uncontrolled renal , hepatic , hematological , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease , sign symptoms 11 . Has know history lymphoproliferative disease , include lymphoma , sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy splenomegaly 12 . History clinically significant drug alcohol abuse 12 month prior baseline . 13 . Female subject pregnant , breastfeeding , plan become pregnant man plan father child enrol study within 20 week last dose study agent . 14 . Subject consider Investigator , reason , unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>Mucosal Healing</keyword>
	<keyword>Certolizumab pegol</keyword>
</DOC>